Publications The melanocortin receptors as targets for general obesity: contextualizing clinical failures and analyzing future perspectivesMarch 11, 2026Dual Activation of MC3R and MC4R Drives Weight Loss and Reduces Food Intake in Obese PrimatesDecember 2, 2025Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in ratsNovember 7, 2024Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexiaOctober 28, 2023Preliminary data from the phase I study of TCMCB07, a study to assess the safety, tolerability and pharmacokinetics of the melanocortin antagonist TCMCB07 in healthy subjectsMay 20, 2023Effect of melanocortin-4 receptor antagonist TCMCB07 on chemotherapy-induced anorexia and weight loss in ratsMay 20, 2023Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-like PeptidesMay 1, 2023Pharmacokinetics and safety of TCMCB07, a melanocortin-4 antagonist peptide in dogsMay 20, 2021Characterization of the cellular transport mechanisms for the anti-cachexia candidate compound TCMCB07July 29, 2020Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease–associated cachexiaJune 16, 2020
The melanocortin receptors as targets for general obesity: contextualizing clinical failures and analyzing future perspectivesMarch 11, 2026
Dual Activation of MC3R and MC4R Drives Weight Loss and Reduces Food Intake in Obese PrimatesDecember 2, 2025
Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in ratsNovember 7, 2024
Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexiaOctober 28, 2023
Preliminary data from the phase I study of TCMCB07, a study to assess the safety, tolerability and pharmacokinetics of the melanocortin antagonist TCMCB07 in healthy subjectsMay 20, 2023
Effect of melanocortin-4 receptor antagonist TCMCB07 on chemotherapy-induced anorexia and weight loss in ratsMay 20, 2023
Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-like PeptidesMay 1, 2023
Characterization of the cellular transport mechanisms for the anti-cachexia candidate compound TCMCB07July 29, 2020
Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease–associated cachexiaJune 16, 2020
